Trial Profile

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Savolitinib (Primary)
Indications Renal cell carcinoma
Focus Proof of concept; Therapeutic Use
Sponsors AstraZeneca

Most Recent Events

18 Apr 2018 Results (n=84) presented at the 109th Annual Meeting of the American Association for Cancer Research.
18 Feb 2017 Preliminary results (Cut off 27 June 2016) presented at the 2017 Genitourinary Cancers Symposium
14 Feb 2017 Results from this trial will be presented at the 2017 Genitourinary Cancers Symposium sponsored by the American Society of Clinical Oncology (ASCO-GU), according to a Chi-Med media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com